285 related articles for article (PubMed ID: 19683776)
1. [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease].
Ardouin C; Chéreau I; Llorca PM; Lhommée E; Durif F; Pollak P; Krack P;
Rev Neurol (Paris); 2009 Nov; 165(11):845-56. PubMed ID: 19683776
[TBL] [Abstract][Full Text] [Related]
2. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
3. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
[TBL] [Abstract][Full Text] [Related]
4. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease.
Merims D; Giladi N
Parkinsonism Relat Disord; 2008; 14(4):273-80. PubMed ID: 17988927
[TBL] [Abstract][Full Text] [Related]
5. Pathological gambling and hypersexuality due to dopaminergic treatment in Parkinson' disease.
Martín Fernández F; Martín González T
Actas Esp Psiquiatr; 2009; 37(2):118-22. PubMed ID: 19401861
[TBL] [Abstract][Full Text] [Related]
6. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
7. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation.
Ardouin C; Voon V; Worbe Y; Abouazar N; Czernecki V; Hosseini H; Pelissolo A; Moro E; Lhommée E; Lang AE; Agid Y; Benabid AL; Pollak P; Mallet L; Krack P
Mov Disord; 2006 Nov; 21(11):1941-6. PubMed ID: 16972268
[TBL] [Abstract][Full Text] [Related]
8. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease.
Miwa H; Morita S; Nakanishi I; Kondo T
Parkinsonism Relat Disord; 2004 Mar; 10(3):177-80. PubMed ID: 15036174
[TBL] [Abstract][Full Text] [Related]
9. Medication-related impulse control and repetitive behaviors in Parkinson's disease.
Voon V; Potenza MN; Thomsen T
Curr Opin Neurol; 2007 Aug; 20(4):484-92. PubMed ID: 17620886
[TBL] [Abstract][Full Text] [Related]
10. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
Bayard S; Cochen De Cock V; Dauvillers Y
Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
[TBL] [Abstract][Full Text] [Related]
11. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.
Avanzi M; Uber E; Bonfà F
Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629
[TBL] [Abstract][Full Text] [Related]
12. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
[TBL] [Abstract][Full Text] [Related]
13. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
14. The Unified Parkinson's Disease Rating Scale: validation study of the mentation, behavior, and mood section.
Starkstein SE; Merello M
Mov Disord; 2007 Nov; 22(15):2156-61. PubMed ID: 17721877
[TBL] [Abstract][Full Text] [Related]
15. Startling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli.
Bowers D; Miller K; Mikos A; Kirsch-Darrow L; Springer U; Fernandez H; Foote K; Okun M
Brain; 2006 Dec; 129(Pt 12):3356-65. PubMed ID: 17095520
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic dysregulation syndrome in Parkinson's disease.
Katzenschlager R
J Neurol Sci; 2011 Nov; 310(1-2):271-5. PubMed ID: 21868039
[TBL] [Abstract][Full Text] [Related]
17. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
Kimber TE; Thompson PD; Kiley MA
J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
19. Impulsive and compulsive behaviors in Parkinson's disease.
Evans AH; Strafella AP; Weintraub D; Stacy M
Mov Disord; 2009 Aug; 24(11):1561-70. PubMed ID: 19526584
[TBL] [Abstract][Full Text] [Related]
20. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
Tomer R; Aharon-Peretz J; Tsitrinbaum Z
Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
